# Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)

> **NCT05029531** · PHASE3 · RECRUITING · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 80 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia, Pediatric
- ALL, Infants

## Interventions

- **COMBINATION_PRODUCT:** the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.

## Key facts

- **NCT ID:** NCT05029531
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-23
- **Primary completion:** 2029-07-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05029531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05029531, "Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05029531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*